Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective

Cardiovascular Journal of Africa

Volumn 21, Issue 1, 2010, Pages 43-46

  Wessels, Francois ^a  

^a NONE

Author keywords

Cardiovascular disease; Fibrate therapy; Pharmaco economics; Type 2 diabetes

Indexed keywords

FENOFIBRATE; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST CONTROL; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SOUTH AFRICA;

EID: 77649156942     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2010-001     Document Type: Article

References (4)

1. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-1861.
2. Carrington Melinda, Stewart Simon. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD study. Int J of Cardiol 2008; 127: 51-56.
3. Rees A. FIELD study. Diabet Med 2006; 23(Suppl 3): 6-12.
4. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697